Flatiron Health at ISPE 2024
Flatiron is excited to attend and present our research at ISPE 2024, showcasing how our evidence solutions can be leveraged to tackle vital questions in oncology pharmacoepidemiology.
Advancing global oncology evidence generation to improve patient outcomes and safety
At Flatiron, we’re constantly pushing the realm of possibilities with evidence solutions that support oncology portfolios across the development lifecycle.
At ISPE, we’re excited to showcase new innovative solutions to advance pharmacoepidemiological evidence generation, including:
-
Local real-world data (RWD) cohorts in the US, UK, Germany and Japan
-
Our prospective evidence generation platform
-
Panoramic RWD solutions in breast and lung cancer
Our research demonstrates Flatiron’s innovative methodologies in electronic health record derived RWD curation and analyses, novel insights informed by our global evidence solutions and expertise, and the feasibility of new methods to reduce the burden of traditional clinical trials.
Featured speaking sessions
FEATURED SESSION
Are you ready for the future? How game-changing technology can unlock the next generation of RWE
Monday, August 26 | 12:30–1:30 PM CEST
Flatiron Health explores the latest technology advancements that are changing the landscape of real-world evidence and pharmacoepidemiology studies, including: machine learning for structured and unstructured data processing, data integrations and analyses to enable prospective evidence generation, and trusted research environments to unlock global real-world studies.
Speakers
Blythe Adamson, PhD, MPH
Flatiron Health
Eric Meadows, PhD
Flatiron Health
Aaron Kamauu, MD, MS, MPH
Navidence
Harriet Dickinson, MPhil, PhD
RWE Director, Gilead
FEATURED SYMPOSIUM
Addressing RWE Transportability Concerns in Health Care Decision-Making. How to Do It Right?
Monday, August 26 | 3:30–5 PM CEST
This symposium addresses the use of real-world evidence (RWE) in healthcare decision-making, focusing on transportability analysis to extend RWE across different populations and settings. Experts will present case studies and methods to address external validity concerns and discuss the implications for decision makers, culminating in a Q&A session.
Speakers
Evie Merinopoulou, MSc
Cytel
Alind Gupta, PhD
Department of Epidemiology, Dalla Lana School of Public Health, University of Toronto
Alessandria Strübing, MSPH
Daiichi Sankyo Europe
Blythe Adamson, PhD, MPH
Flatiron Health
Stephen Duffield, PhD
National Institute of Health and Care Excellence (NICE)
Featured solutions
Real-world data cohorts in the UK, Germany, and Japan for global evidence generation
Flatiron’s local data in Germany, UK, and Japan fill a critical gap in global real-world evidence generation with the clinical depth and recency required to conduct rigorous pharmacoepidemiology studies.
Streamlined services and clinical research technology for more efficient studies
Our prospective evidence generation platform builds on our retrospective RWE capabilities to unlock safety, efficacy and post-marketing studies.
A comprehensive, disease-specific solution for breast and lung cancer
Flatiron’s Panoramic Solutions, our largest real-world data cohorts in breast and lung cancer, can be leveraged to maximize use cases across your oncology portfolio.
Our featured experts at ISPE
Blythe Adamson, PhD, MPH
Head, Outcomes Research & Evidence Generation, International
Our research
Read more about our accepted research at this year’s conference.
Characterization of novel longitudinal oncology real-world datasets in Germany and the UK: Biomarker prevalence findings
Author affiliations: Flatiron Health
Currently, real-world oncology data with the clinical depth and recency necessary to conduct rigorous pharmacoepidemiology studies is limited in Europe. The study identified a cohort of more than 1,000 patients with cancer in Germany and UK for prospective longitudinal observational studies, resulting in datasets designed to be fit-for-purpose for oncology treatment comparative-effectiveness research and pooling across countries, opening doors for further research.
See this research
Date: Tuesday, August 27
Time: 8 AM – 6 PM
Poster Session: B
Poster Code: 12
Connect with a flatiron expert
Blythe Adamson, PhD, MPH
Head, Outcomes Research & Evidence Generation, International
Connect on LinkedIn
Feasibility of prospective real-world studies to fulfill regulatory commitments and requirements in oncology within the United States
Author affiliations: Flatiron Health
Postmarketing commitments/requirements (PMRs) are common in oncology, especially with accelerated approvals. However, to obtain fit-for-purpose data, prospective study designs are often needed. This research found that pragmatic, prospective studies, designed to leverage a combination of routinely collected clinical data and intentionally captured data, can improve the efficiency of PMR fulfillment within the US regulatory environment.
See this research
Date: Monday, August 26
Time: 8 AM – 6 PM
Poster Session: A
Poster Code: 57
Connect with a flatiron expert
Eric Meadows, PhD
Director, Scientific Engagement
Connect on LinkedIn
An evaluation of patient activity definitions and informative censoring in analyses of real-world overall survival in electronic health records (EHR) in the United States
Author affiliations: Flatiron Health
Ensuring accurate results for rwOS for use in research is paramount. This study explores the utility of abstracted data in defining the censor date and signaling the potential for informative censoring and highlights EHR-derived real-world data’s ability to signal possible biases impacting the validity rwOS analyses.
See this research
Date: Wednesday, August 28
Time: 8 AM – 6 PM
Poster Session: C
Poster Code: 139
Connect with a flatiron expert
Raina Mathur, MPH
Director, Research Sciences
Connect on LinkedIn
Assessing the potential value of commercial mortality data combined with publicly available death data for pharmacoepidemiology research
Author affiliations: Flatiron Health
The National Death Index is considered a gold standard for mortality data, but its utility in research is limited due to the time lag. This study demonstrates the reliability of a combined approach using obituary data and US Social Security Death Index, even without access to EHR data, offering a valuable alternative for mortality assessment in non-oncology research.
See this research
Date: Wednesday, August 28
Time: 8 AM – 6 PM
Poster Session: C
Poster Code: 142
Connect with a flatiron expert
Eric Meadows, PhD
Director, Scientific Engagement
Connect on LinkedIn
Assessment of the application of a 90-day-gap rule for mitigating frontline treatment sequence misclassification in electronic health records in the United States
Author affiliations: Flatiron Health
Defining frontline therapy using EHR-derived data is complex as treatment data from various networks may not always be readily available in the structured elements of the patient record. This study evaluated Flatiron’s 90-day-gap rule’s ability to flag patients with treatment misclassification due to missing frontline treatment information, providing a path forward to increase the number of patients available for analysis, particularly important when studying rare disease cohorts. The research also demonstrated the low prevalence of misclassification of frontline treatment data in Flatiron data.
See this research
Date: Wednesday, August 28
Time: 8 AM – 6 PM
Poster Session: C
Poster Code: 143
Connect with a flatiron expert
Mark Guinter, PhD
Senior Research Scientist
Connect on LinkedIn
Request a meeting
Looking for support in tackling your next pharmacoepidemiological research question?
Leverage Flatiron’s industry-leading oncology solutions to unlock global insights in pharmacoepidemiology research, including:
-
Real-world data cohorts in the US, UK, Germany, and Japan for global evidence generation
-
Prospective evidence generation platform to unlock safety, efficacy and post-marketing studies
-
Comprehensive, disease-specific solutions to maximize use cases across your oncology portfolio
Contact us to learn more about Flatiron’s tailored oncology evidence solutions.